Elevance Health Faces Medicare Advantage Enrollment Suspension Over Data Issues
Elevance Health shares plunged more than 8% Monday as the Centers for Medicare & Medicaid Services (CMS) moved to suspend the company from enrolling new members into its Medicare Advantage plans. The action, described as a “harshly worded suspension notice” by health policy reporter Bob Herman, stems from Elevance’s failure to provide required data to federal regulators over a period of seven years. This development raises significant questions about the financial stability of one of the nation’s largest health insurers and the broader landscape of Medicare Advantage, a program increasingly relied upon by seniors.
What the Suspension Means for Current Enrollees
Crucially, the suspension will not immediately impact the approximately 1.9 million individuals already enrolled in Elevance Medicare Advantage plans for this year. CMS has indicated that it will allow current members to continue receiving coverage uninterrupted. However, the inability to attract new enrollees during the critical Medicare annual enrollment period, which begins in October, could severely hamper Elevance’s financial performance. The company could potentially reverse the suspension if it addresses the data submission issues this month, according to CMS.
A Rare and Serious Sanction
CMS rarely imposes such stringent penalties on Medicare Advantage providers. The severity of the sanction underscores the agency’s concern regarding Elevance’s compliance with reporting requirements. These requirements are designed to ensure transparency and accountability within the Medicare Advantage program, allowing CMS to accurately assess plan quality, and performance. The agency’s action signals a willingness to hold insurers accountable for fulfilling their obligations, even those with substantial market share. A similar case unfolded last year, with Elevance losing a lawsuit against CMS over Medicare Advantage star ratings, as reported by STAT News in August 2025. The judge in that case, appointed by former President Trump, reportedly criticized Elevance’s arguments as ignoring “basic math.”
The Data Submission Issues: A Seven-Year Pattern
The core of the issue lies in Elevance’s consistent failure to submit necessary information to CMS over a seven-year timeframe. The specific nature of the missing data hasn’t been publicly detailed, but it’s likely related to reporting on quality metrics, enrollment figures, or financial performance. Accurate data is essential for CMS to evaluate the effectiveness of Medicare Advantage plans and ensure they are providing adequate care to beneficiaries. Without this information, the agency’s ability to oversee the program is compromised.
Medicare Advantage: A Growing Program Under Scrutiny
This situation unfolds against a backdrop of increasing scrutiny of the Medicare Advantage program. Originally intended to offer seniors more choices and potentially lower costs, Medicare Advantage has grown rapidly in recent years, now covering more than half of all Medicare beneficiaries. However, concerns have been raised about potential issues such as:
- Risk Adjustment: Insurers receive payments based on the health risk of their enrollees. We find concerns that some plans may be inaccurately assessing risk, leading to overpayments.
- Marketing Practices: Aggressive marketing tactics have been criticized for potentially misleading seniors about plan benefits and limitations.
- Denial of Care: Reports suggest that some Medicare Advantage plans may be inappropriately denying necessary care to control costs.
In November 2025, STAT News reported on concerns that health insurers were attempting to avoid enrolling new Medicare beneficiaries with costly health conditions. This adds to the broader narrative of potential issues within the program.
What Happens Next: CMS Oversight and Elevance’s Response
The immediate next step involves Elevance’s response to the CMS suspension notice. The company has a limited window to address the data submission issues and demonstrate compliance. If Elevance fails to do so, the enrollment suspension will likely remain in place, potentially leading to significant financial repercussions. CMS will continue to monitor the situation closely and may take further action if necessary.
Beyond this specific case, the incident is likely to prompt increased scrutiny of other Medicare Advantage providers. CMS may conduct more frequent audits and tighten reporting requirements to ensure greater compliance across the industry. The agency is also likely to face renewed pressure from lawmakers and advocacy groups to address the broader concerns surrounding the Medicare Advantage program.
The Broader Implications for Medicare Beneficiaries
While current Elevance enrollees are not immediately affected, the situation highlights the importance of carefully evaluating Medicare Advantage plans during the annual enrollment period. Beneficiaries should thoroughly research plan benefits, coverage limitations, and quality ratings before making a decision. Resources like the Medicare.gov website provide valuable information to assist seniors navigate the complexities of the program. It’s also crucial to understand that Medicare Advantage plans are not a one-size-fits-all solution and may not be the best option for everyone. Traditional Medicare, with or without a supplemental Medigap policy, remains a viable alternative.
The unfolding situation with Elevance serves as a stark reminder of the challenges facing the Medicare Advantage program and the need for robust oversight to protect the interests of beneficiaries. The coming months will be critical in determining whether Elevance can resolve the issues and regain CMS’s trust, and what broader implications this case will have for the future of Medicare Advantage.